Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
Why Is Immunic Stock Falling 5% Following Its Third-Quarter Results?
Immunic shares fall 5% on third quarter earnings miss
Immunic: Q3 Earnings Snapshot
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Immunic Q3 EPS $(0.99) Misses $(0.96) Estimate
Immunic CEO discusses Q3 highlights and December Phase 3 MS trial readouts
Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development Transcript
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
Immunic, Inc. (IMUX) Progressive Multiple Sclerosis R&D Day: Vidofludimus Calcium Development - Slideshow
Immunic to Participate in Investor Conferences in November
Immunic highlights progressive MS research and Phase 3 outlook at MSToronto2026
Immunic to host R&D Day on progressive multiple sclerosis
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
Immunic, Inc. (IMUX) Presents at 10th Joint ACTRIMS-ECTRIMS Meeting - MSToronto2026 - Slideshow
Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic to showcase phase 2 long-term MS disability data at MSToronto2026
Immunic adds new Chief People Officer ahead of Phase 3 readout
Immunic Appoints Jaa Roberson as Chief People Officer
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.